Barrington lowered the firm’s price target on Orthofix (OFIX) to $17 from $18 and keeps an Outperform rating on the shares. The company reported solid Q4 results but its longer term adjusted EBITDA margin target is pushed out to 2028 from 2027, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OFIX:
- Orthofix reports Q4 EPS (6c) vs. (75c) last year
- Orthofix sees FY26 revenue $850M-$860M, consensus $862.76M
- Orthofix Posts Strong Q4 Results and Optimistic 2026 Outlook
- Is OFIX a Buy, Before Earnings?
- Orthofix: Turnaround Fundamentals Improving but Revenue Visibility Delays Re-Rating, Justifying Hold and $14 Target